Glucagon-GLP-1-GIP triple agonist compounds
US11111285B2 · kind B2 · utility
0Cited by
103References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 4, 2018 |
| Grant date | Sep 7, 2021 |
| Priority date | — |
| Expiry date | Oct 4, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.